Rockwell Medical, Inc. (RMTI) agreed to acquire Vantive Limited’s in-center hemodialysis business in 35 jurisdictions, including two operating entities, other business assets and related liabilities. The $125 million base purchase price is subject to adjustments; closing consideration is structured as seller financing through two $50 million term loans and a $25 million convertible note. Vantive may also receive up to $45 million in earnout payments tied to pro forma EBITDA and revenue milestones.
The transaction is expected to close in mid-2027, subject to regulatory approvals and other conditions, including Vantive’s pre-closing reorganization and separation from Baxter’s information technology systems. The term loans mature six years after closing and carry margins that increase annually. The note bears 3.0% annual interest paid in kind and has an initial $14.94 conversion price; until stockholder approval, conversion share issuance is capped at 19.99% of shares or voting power outstanding immediately before the Purchase Agreement. RMTI withdrew its 2026 guidance for Net Sales, Gross Margin, Adjusted EBITDA and Operating Cash Flow due to projected transaction- and financing-related expenses. RMTI estimates the combined business could generate annual revenue between $400 million and $450 million based on current assumptions.
Rockwell Medical, Inc. (RMTI) President and CEO Mark Strobeck reported a sale of 1,000 shares of common stock at $8.42 per share on October 1, 2026. Following the transaction, his directly held position was 61,349 shares. The sale was executed under a Rule 10b5-1 trading plan that Mark Strobeck adopted on May 19, 2026.
Rockwell Medical, Inc. (RMTI) officer Mark Strobeck is named as the person for whose account 1,000 common shares would be sold through Raymond James & Associates, Inc.; the reported aggregate market value is $8,400.00. The approximate sale date is October 1, 2026, and the listed exchange is Nasdaq. The notice also lists 4,030,465 shares outstanding.
Rockwell Medical, Inc. furnished an updated corporate presentation as a Regulation FD Disclosure. The presentation, dated August 13, 2026, is provided as Exhibit 99.1 and is incorporated by reference. The materials are furnished, not filed, so they are not subject to Section 18 liabilities and are not automatically incorporated into Securities Act or Exchange Act filings.
Rockwell Medical, Inc. reported modest top-line growth and narrower losses for the quarter and six months ended June 30, 2026. Second-quarter net sales were $17.8 million, up 11% from a year earlier, driven mainly by $1.3 million of sales to new customers in the Western U.S. and price increases to existing accounts. Gross profit rose to $3.2 million with margin improving to 18% from 16%, helped by lower manufacturing headcount and overhead.
For the first half of 2026, net sales were $35.1 million, essentially flat year over year, as growth from new and existing customers offset a $4.3 million decline in sales to DaVita and the absence of $0.3 million of prior-year license revenue. Net loss for the six months narrowed to $2.8 million from $3.0 million, and operating cash flow turned positive at $1.9 million versus a $1.6 million outflow. The company ended the quarter with $24.8 million in cash, cash equivalents and available-for-sale investments, working capital of $25.2 million, and term loans of $9.0 million outstanding under an interest-only structure through early 2027. A 1-for-10 reverse stock split became effective July 1, 2026 to regain Nasdaq minimum bid compliance; all share data are presented on a split-adjusted basis. Management states it believes current resources are sufficient to fund operations for at least 12 months while it continues cost containment and pursues additional growth and potential capital-raising options, including $13.1 million remaining under its at-the-market equity program.
Rockwell Medical, Inc. reported second quarter 2026 net sales of $17.8 million, up 11% from $16.1 million a year earlier, driven by new customers in the Western U.S. and higher purchasing from existing customers. Gross profit rose to $3.2 million, a 30% increase, and gross margin expanded to 18% from 16% as lower manufacturing costs and higher volume improved profitability.
The company recorded a net loss of $1.2 million for the quarter, improving from a $1.5 million loss a year ago and $1.6 million in the first quarter of 2026. Adjusted EBITDA was a loss of $0.2 million, similar to the prior year period, while operating cash flow turned positive at $2.1 million, lifting cash, cash equivalents and investments to $24.8 million as of June 30, 2026.
For full-year 2026, Rockwell Medical reiterates guidance of $70–$75 million in net sales, gross margin of 18%–22%, Adjusted EBITDA of $1–$2 million, and positive operating cash flow. During the quarter it signed and extended multi-year product purchase agreements with dialysis providers and completed a 1-for-10 reverse stock split, after which it regained compliance with Nasdaq’s minimum bid price requirement.
Rockwell Medical, Inc. reported that it has received notice from Nasdaq that the company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The shares maintained a closing bid of at least $1.00 from July 1, 2026 through July 15, 2026, and Nasdaq has closed the compliance matter. The company states it is now in full compliance with all Nasdaq continued listing requirements, and its common stock remains listed and traded under the ticker RMTI.
Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide, focused on supporting patients with end-stage kidney disease.
Dawson Joseph H reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical director Joseph H. Dawson received an equity grant and his holdings were adjusted for a reverse split. On July 1, 2026, he was granted 9,633 shares in the form of restricted stock units at no cash cost. These units vest on July 1, 2027, if he continues serving through the 2027 annual meeting. Effective at 12:01 a.m. on July 1, 2026, Rockwell Medical completed a 1-for-10 reverse split of its common stock, and his existing shareholdings and equity awards were proportionately reduced. After giving effect to both the grant and the reverse split adjustments, Dawson beneficially owns 12,133 shares of common stock directly.
Nissenson Allen reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Allen Nissenson received a grant of 9,633 shares of Common Stock as a compensation award, recorded at a price of $0.0000 per share. These shares are in the form of restricted stock units that vest on July 1, 2027, subject to his continued service through the 2027 annual meeting.
The company also completed a 1-for-10 reverse split of its common stock effective 12:01 a.m. on July 1, 2026, which reduced the number of shares held and adjusted outstanding equity awards. After these changes and the grant, Nissenson beneficially owns 23,892 shares directly.
Lau Joan reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Joan Lau received a grant of 9,633 shares of Common Stock as a stock award, with no cash paid per share. These restricted stock units vest on July 1, 2027, subject to her continued service through the 2027 Annual Meeting. A 1-for-10 reverse split effective July 1, 2026 adjusted her holdings to 20,944 shares after the reported grant.